Compare Li Auto Inc (LI) vs Novavax Inc (NVAX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Li Auto Inc vs Novavax Inc — how do they compare? Li Auto Inc trades at $11.54 (market cap $10.71B), while Novavax Inc trades at $12.75 (market cap $1.82B). The key difference: Li Auto Inc is far larger — about 5.9× Novavax Inc's market cap, and Novavax Inc is trading nearer its 52-week high, Li Auto Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Li Auto Inc for 101 Days and Novavax Inc for 59 Days on average.
| LI | NVAX | |
|---|---|---|
Market Cap | $10.71B | $1.82B |
Volume | 1,781,143 | 6,198,505 |
Sector | Consumer Cyclical | Health |
52-Week High | $23.61 | $12.56 |
52-Week Low | $10.69 | $6.22 |
Typical Hold Time | 101 Days | 59 Days |
Enterprise Value | $139.58M | $1.39B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Li Auto (LI) trades at $11.54, down 5.0% recently and near 52-week lows amid weak delivery numbers. The stock shows bearish technical signals with negative moving averages, while fundamentals reveal declining revenue from $144.5B in 2024 to $112.3B in 2025 and negative net income margins. Recent news highlights September deliveries of 31,817 vehicles and new model launches like the Li i9 SUV.
Outlook remains challenging with intense EV competition and cash flow concerns, though analyst consensus suggests 32% upside to $15.18 target. Key risks include execution on new models and Chinese market volatility, while the strong balance sheet provides some stability for patient investors.
Novavax (NVAX) trades at $12.75, up 13.64% with strong technical momentum and bullish moving averages. The company shows mixed fundamentals with revenue of $1.12B in 2025 and positive net income of $440.30M, though 2026 projections indicate a return to losses. Recent news highlights regulatory approvals for its COVID-19 vaccine and strategic pivot toward Matrix-M adjuvant licensing partnerships.
The outlook remains speculative with high volatility. Opportunities include partnership-driven growth and vaccine demand, but risks involve consistent profitability challenges, high debt-to-asset ratios, and competitive pressures. Analyst sentiment is predominantly bullish (73.9% buy ratings), yet investors should weigh the company's transition phase against financial stability concerns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Li Auto Inc
Li Auto is a leading Chinese NEV manufacturer that designs, develops, manufactures, and sells premium smart NEVs. The company started volume production of its first model Li One in November 2019. The model is a six-seater, large, premium plug-in electric SUV equipped with a range extension system and advanced smart vehicle solutions. It sold over 90,000 EVs in 2021, accounting for about 2.7% of China's passenger new energy vehicle market. Beyond Li One, the company will expand its product line, including both BEVs and PHEVs, to target a broader consumer base.
Read more on LI →About Novavax Inc
Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.
Read more on NVAX →
